[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100448044":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":20,"responsibleParty":41,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":10,"maxAge":10,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":10,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Charite University, Berlin, Germany","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Cohort 1",null,"Systemic (= localized outside the CNS) lymphoma with secondary CNS involvement at initial diagnosis",{"label":13,"type":10,"description":14,"interventionNames":10},"Cohort 2","CNS relapse of previously systemic lymphoma",[16],{"name":17,"role":18,"phone":10,"phoneExt":10,"email":19},"Stefan Habringer, MD","CONTACT","stefan.habringer@charite.de",[21],{"facility":22,"status":23,"city":24,"state":10,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Charité - Universitätsmedizin, Med. Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie (CBF)","RECRUITING","Berlin","12200","Germany","DE",{"type":29,"coordinates":30},"Point",[31,32],13.41053,52.52437,{"lat":32,"lon":31},[35,39],{"name":36,"role":18,"phone":37,"phoneExt":10,"email":38},"Ulrich Keller, MD, Prof.","+4930 450513447","ulrich.keller@charite.de",{"name":17,"role":18,"phone":40,"phoneExt":10,"email":19},"+4930450613549",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Stefan Habringer","Principal Investigator","100448044","secondary-central-nervous-system-lymphoma-registry---charit-100448044",false,"NCT05114330","Secondary Central Nervous System Lymphoma Registry - Charité","Non-interventional, Prospective Observational Study of the Treatment Practice of CNS Involvement of Malignant Lymphoma in Routine Clinical Practice","Inclusion Criteria:\n\n• All patients with SCNSL can and should be included in the registry regardless of which treatment options are used and whether the treatment being given is first-line, recurrence, or maintenance therapy for SCNSL.\n\nExclusion Criteria:\n\n• None","ALL",{"count":54,"type":55},300,"ESTIMATED","3 Years","OBSERVATIONAL","The objective of the observation is to collect and document data on treatment strategies for secondary central nervous system lymphoma (SCNSL) in routine clinical practice, whether obtained in the context of clinical trials or outside of trials. In particular, the following questions will be specified:\n\n* What therapeutic approaches are being pursued?\n* What is the clinical outcome of the various treatment options?\n* What is the frequency of serious adverse events with each therapeutic approach?",[60,61],"Central Nervous System Lymphoma","Non-Hodgkin Lymphoma","2023-11-23",{"date":64,"type":65},"2023-11-27","ACTUAL",{"date":67,"type":65},"2011-06-08",{"date":69,"type":55},"2026-06-08",{"name":5,"class":6},1]